Literature DB >> 22574931

NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation.

Adam W Barb1, Lu Meng, Zhongwei Gao, Roy W Johnson, Kelley W Moremen, James H Prestegard.   

Abstract

The terminal carbohydrate residues of the N-glycan on the immunoglobulin G (IgG) fragment crystallizable (Fc) determine whether IgG activates pro- or anti-inflammatory receptors. The IgG Fc alone becomes potently anti-inflammatory upon addition of α2-6-linked N-acetylneuraminic acid residues to the N-glycan, stimulating interest in use of this entity in novel therapies for autoimmune disease [Kaneko et al. (2006) Science313, 670-3]. Complete Fc sialylation has, however, been deemed challenging due to a combination of branch specificity and perceived protection by glycan-protein interactions. Here we report the preparation of high levels of disialylated Fc by using sufficient amounts of a highly active α2-6 sialyltransferase (ST6Gal1) preparation expressed in a transiently transformed human cell culture. Surprisingly, ST6Gal1 sialylated the two termini of the complex-type binantennary glycan in a manner remarkably similar to that observed for the free N-glycan, suggesting the Fc polypeptide does not greatly influence ST6Gal1 specificity. In addition, sialylation of either branch terminus does not appear to dramatically alter the motional behavior of the N-glycan as judged by solution NMR spectroscopy. Together these, data suggest the N-glycan occupies two distinct states: one with both glycan termini sequestered from enzymatic modification by an α1-6Man-branch interaction with the polypeptide surface and the other with both glycan termini exposed to the bulk solvent and free from glycan-polypeptide interactions. The results suggest new modes by which disialylated Fc can act as an anti-inflammatory effector.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22574931      PMCID: PMC3447994          DOI: 10.1021/bi300319q

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  34 in total

1.  The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex.

Authors:  P Sondermann; R Huber; V Oosthuizen; U Jacob
Journal:  Nature       Date:  2000-07-20       Impact factor: 49.962

2.  Sialyl- and fucosyltransferases in the biosynthesis of asparaginyl-linked oligosaccharides in glycoproteins. Mutually exclusive glycosylation by beta-galactoside alpha2 goes to 6 sialyltransferase and N-acetylglucosaminide alpha1 goes to 3 fucosyltransferase.

Authors:  J C Paulson; J P Prieels; L R Glasgow; R L Hill
Journal:  J Biol Chem       Date:  1978-08-25       Impact factor: 5.157

3.  Comparison of the binding of radiolabelled human IgG and Fc fragments to murine spleen cells.

Authors:  E L Morgan; H L Spiegelberg; W O Weigle
Journal:  Scand J Immunol       Date:  1979       Impact factor: 3.487

4.  Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution.

Authors:  J Deisenhofer
Journal:  Biochemistry       Date:  1981-04-28       Impact factor: 3.162

5.  Altered granulopoietic profile and exaggerated acute neutrophilic inflammation in mice with targeted deficiency in the sialyltransferase ST6Gal I.

Authors:  Mehrab Nasirikenari; Brahm H Segal; Julie R Ostberg; Ashlee Urbasic; Joseph T Lau
Journal:  Blood       Date:  2006-07-18       Impact factor: 22.113

6.  Glycosyltransferases of the human cervical epithelium. I. Characterization of a beta-galactoside alpha-2-L-fucosyltransferase and the identification of a beta-N-acetylglucosaminide alpha-3-L-fucosyltransferase.

Authors:  P R Scudder; E N Chantler
Journal:  Biochim Biophys Acta       Date:  1981-07-24

7.  Branch specificity of bovine colostrum CMP-sialic acid: Gal beta 1----4GlcNAc-R alpha 2----6-sialyltransferase. Sialylation of bi-, tri-, and tetraantennary oligosaccharides and glycopeptides of the N-acetyllactosamine type.

Authors:  D H Joziasse; W E Schiphorst; D H Van den Eijnden; J A Van Kuik; H Van Halbeek; J F Vliegenthart
Journal:  J Biol Chem       Date:  1987-02-15       Impact factor: 5.157

8.  Cloning, expression, purification, and characterization of the acid alpha-mannosidase from Trypanosoma cruzi.

Authors:  A S Vandersall-Nairn; R K Merkle; K O'Brien; T N Oeltmann; K W Moremen
Journal:  Glycobiology       Date:  1998-12       Impact factor: 4.313

9.  Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG.

Authors:  R B Parekh; R A Dwek; B J Sutton; D L Fernandes; A Leung; D Stanworth; T W Rademacher; T Mizuochi; T Taniguchi; K Matsuta
Journal:  Nature       Date:  1985 Aug 1-7       Impact factor: 49.962

Review 10.  Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications.

Authors:  J G van de Winkel; P J Capel
Journal:  Immunol Today       Date:  1993-05
View more
  68 in total

1.  Characterization of the interaction between Robo1 and heparin and other glycosaminoglycans.

Authors:  Fuming Zhang; Heather A Moniz; Benjamin Walcott; Kelley W Moremen; Robert J Linhardt; Lianchun Wang
Journal:  Biochimie       Date:  2013-08-28       Impact factor: 4.079

2.  From Rhesus macaque to human: structural evolutionary pathways for immunoglobulin G subclasses.

Authors:  William David Tolbert; Ganesh Prasad Subedi; Neelakshi Gohain; George Kenneth Lewis; Kashyap Rajesh Patel; Adam Wesley Barb; Marzena Pazgier
Journal:  MAbs       Date:  2019-04-02       Impact factor: 5.857

3.  Reply to Crispin et al.: Molecular model that accounts for the biological and physical properties of sialylated Fc.

Authors:  Peter Sondermann; Andrew Pincetic; Jad Maamary; Katja Lammens; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-17       Impact factor: 11.205

4.  Crystal structure of sialylated IgG Fc: implications for the mechanism of intravenous immunoglobulin therapy.

Authors:  Max Crispin; Xiaojie Yu; Thomas A Bowden
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-08       Impact factor: 11.205

5.  Carbohydrate-Polypeptide Contacts in the Antibody Receptor CD16A Identified through Solution NMR Spectroscopy.

Authors:  Ganesh P Subedi; Daniel J Falconer; Adam W Barb
Journal:  Biochemistry       Date:  2017-06-16       Impact factor: 3.162

6.  Selective exo-enzymatic labeling of N-glycans on the surface of living cells by recombinant ST6Gal I.

Authors:  Ngalle Eric Mbua; Xiuru Li; Heather R Flanagan-Steet; Lu Meng; Kazuhiro Aoki; Kelley W Moremen; Margreet A Wolfert; Richard Steet; Geert-Jan Boons
Journal:  Angew Chem Int Ed Engl       Date:  2013-10-15       Impact factor: 15.336

7.  The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor.

Authors:  Ganesh P Subedi; Adam W Barb
Journal:  MAbs       Date:  2016-08-05       Impact factor: 5.857

8.  Immunoglobulin G1 Fc domain motions: implications for Fc engineering.

Authors:  Martin Frank; Ross C Walker; William N Lanzilotta; James H Prestegard; Adam W Barb
Journal:  J Mol Biol       Date:  2014-02-09       Impact factor: 5.469

9.  Mucin-type O-glycosylation is controlled by short- and long-range glycopeptide substrate recognition that varies among members of the polypeptide GalNAc transferase family.

Authors:  Leslie Revoredo; Shengjun Wang; Eric Paul Bennett; Henrik Clausen; Kelley W Moremen; Donald L Jarvis; Kelly G Ten Hagen; Lawrence A Tabak; Thomas A Gerken
Journal:  Glycobiology       Date:  2015-11-26       Impact factor: 4.313

10.  Cell-Surface Glyco-Engineering by Exogenous Enzymatic Transfer Using a Bifunctional CMP-Neu5Ac Derivative.

Authors:  Chantelle J Capicciotti; Chengli Zong; M Osman Sheikh; Tiantian Sun; Lance Wells; Geert-Jan Boons
Journal:  J Am Chem Soc       Date:  2017-09-15       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.